核子醫學攝影系統及設備的全球市場(2011-2016年):正電子放射斷層攝影(PET)和單光子射出電腦斷層掃描(SPECT)的展望 是由出版商Markets and Markets在2011年10月所出版的。
這份英文市場調查報告書價格從美金4650起跳。
本報告提供正電子放射斷層攝影(PET)和單光子射出電腦斷層掃描(SPECT)的全球市場相關調查分析，相關產品的開發和服務提供的主要企業的策略和推動市場成長要素，阻礙因素等資料彙整，概述為以下內容。
目錄
第1章 簡介
- 最重要的一點
- 關於本報告書
- 調查對象市場
- 利害關係者
- 調查手法
第2章 摘要整理
第3章 市場概況
- 簡介
- PET及SPECT技術的發展
- PET和SPECT的差異
- 混合型影像 VS 自立型元件
- 最終消費者相關分析
- 市場動態
- 趨勢
- 勝利的秘訣
- 重大的問題
- 美國的醫療改革
- SPECT的原料不足
- PET/MRI
- PET的新興成長市場
- PET的新的治療的用法
- 低成本生產據點轉變的價格下降:TAG
- 關注印度的GE HEALTHCARE
- POSITRON CORPORATION的與中國企業的合資事業
- 新興加入此市場的SIEMENS HEALTHCARE
- 市場佔有率相關分析
第4章 不同技術中的PET市場與SPECT市場
- PET
- 自立型PET
- 混合型PET技術
- SPECT
- 自立型SPECT
- SPECT/CT
第5章 不同用途中的PET市場與SPECT市場
第6章 各地區分析
第7章 競爭環境
第8章 企業簡介
Abstract
Report Description
Global Nuclear Imaging Systems / Equipment Market (2011 - 2016) - PET
(Positron Emission Tomography) & SPECT (Single Photon Emission Computed
Tomography) Landscape
The global economy is heading towards a double dip phenomenon. The scenario is
not very conducive for high-end capital equipments such as PET and SPECT
scanners. This is delaying the purchase of new equipments and boosting the
market for refurbished instruments.
Increasing awareness among the physicians with respect to nuclear imaging
techniques, mounting application areas such as neurological diseases, and
rising cases in oncology are driving the PET and SPECT imaging market.
Increasing aging population and widening applications of PET and SPECT imaging
due to continuous developments and discovery of new radiopharmaceuticals are
predominantly driving the diagnostic imaging market.
The emerging trend catching interest of the players is fusion of nuclear
imaging with different modalities of diagnostic imaging products. The merging
of imaging modalities such as PET/CT, SPECT/CT, and MRI/PET helps in providing
full gamut of imaging scans through the same unit and at the same time.
Further, portable diagnostic equipment are facing an immense demand from
physicians.
PET is more preferred as compared to SPECT imaging as PET provides higher
resolution images, and the lack of availability of technetium-99m for SPECT is
forcing the medical community and the industry to look for alternatives. On
the other hand, the high cost of PET restricts its use in cost sensitive
markets.
PET is predominately used in oncology as the quality of image provided gives
more comprehensive information about the tumor. SPECT, on the other hand,
holds 90% share in cardiology. PET is catching up with new
radiopharmaceuticals, specifically for cardiac PET.
The U.S. accounts for the highest share of the global PET and SPECT market;
followed by Europe. Asia-Pacific (excluding Japan) stands third. The growth in
the medical device industry has been spurred by Asian economies (China and
India) and a few countries of South America (Brazil and Peru). Rest of the
world is still lagging behind in nuclear imaging market.
Aging population and increase in the chronic disease population are considered
as the main drivers of the PET and SPECT market in the developed nations and
rising fiscal deficit and economic recession are expected to inhibit the
growth of the developed nations.
The PET and SPECT market is highly consolidated with most of it being held by
a few major players. GE Healthcare (U.K.), Philips (The Netherlands), and
Siemens (Germany) together constitute above 85% of the market. GE Healthcare
is a leading player due to better accompanying services along with the
products. The other players trying to make an entry into the niche market are
Positron Corporation (U.S), Spectrum (U.S), and Naviscan (U.S).
Scope of the report
Global PET and SPECT imaging market research report evaluates the global
market of PET (Positron Emission Tomography) and SPECT (Single Photon Emission
Computed Tomography) imaging with respect to the product and application
market. The report analyzes geography; forecasting revenue, and trends in each
of the following submarkets:
" PET " PET/CT " SPECT " SPECT/CT PET and SPECT market is also considered by
the types of applications:
" Oncology " Cardiology " Neurology The geographies covered under the report
are
" North America " Europe " Asia-Pacific (excluding Japan) " Japan " Rest of
the World Each section provides market data, market drivers, trends and
opportunities, key players, and competitive outlook. The report does provide
market tables for covering the sub-segments and micro-markets. Additionally,
it makes ways for company profiles that cover all the sub-segments. The report
has been made by keeping past trends, current happenings and future forecasts
in minds.
Summary
Global PET and SPECT Equipment Market
This study analyses the competitive scenario of the world PET and SPECT
imaging market and the strategies employed by the key industry players to
develop products and services.
The number of installations is high for SPECT due to the lower cost. The
installation market is expected to grow at a CAGR of 4.7% from 2011 to 2016.
There is continuous development in technology that has led to the introduction
of innovative products such as PET/MR.
PET and SPECT technologies, when compared to each other, have many
differences; for instance PET radiopharmaceuticals emit positrons (two rays
simultaneously), whereas SPECT radiopharmaceuticals emit gamma radiations, as
PET has two electrons. At the same time, PET requires a higher number of
cameras to capture them, thereby increasing the cost. Besides, PET
radiopharmaceuticals require a cyclotron for production, escalating the cost
further. On the other hand, the quality of image generated through PET is far
better then that through SPECT.
The availability of radiopharmaceutical for SPECT (Technetium) is a major
restraint, restricting the SPECT market. There is an ongoing research for
developing technetium from accelerators, as the current methods are not able
to meet the requirements. SPECT has the largest share in cardiology
applications, whereas PET has dominance in oncology.
Table of Contents
1 INTRODUCTION
- 1.1 KEY TAKE-AWAYS
- 1.2 REPORT DESCRIPTION
- 1.3 MARKETS COVERED
- 1.4 STAKEHOLDERS
- 1.5 RESEARCH METHODOLOGY
- 1.5.1 MARKET SIZE
- 1.5.2 MARKET SHARE
- 1.5.3 KEY DATA POINTS FROM SECONDARY SOURCES
- 1.5.4 KEY DATA POINTS FROM PRIMARY SOURCES
- 1.5.5 ASSUMPTIONS
2 EXECUTIVE SUMMARY
3 MARKET OVERVIEW
- 3.1 INTRODUCTION
- 3.2 EVOLUTION OF PET & SPECT TECHNOLOGY
- 3.2.1 EVOLUTION OF PET
- 3.2.1.1 Challenges in early stages
- 3.2.1.2 Concerted efforts to resolve concerns of infrastructure &
finance
- 3.2.1.2.1 Facilities to purchase patient-specific doses
- 3.2.1.2.2 Limited financial risk for hospitals
- 3.2.2 EVOLUTION OF SPECT
- 3.3 DIFFERENCE BETWEEN PET & SPECT
- 3.4 HYBRID IMAGING VS STANDALONE MODULES
- 3.5 END-USER ANALYSIS
- 3.6 MARKET DYNAMICS
- 3.6.1 DRIVERS & RESTRAINTS
- 3.6.1.1 Rising incidence of cancer & cardiac diseases to push the
sales of scanners
- 3.6.1.2 Approval of florbetapir to increase the sales of scanners
- 3.6.1.3 Greater accuracy & insights of the diseases compared to other
diagnostic methods
- 3.6.1.4 Economic downturn to affect the overall PET-SPECT market
- 3.6.2 OPPORTUNITIES
- 3.6.2.1 Untapped market of emerging countries
- 3.6.2.2 Non-linear fusion capability allows manipulations for better
image quality
- 3.7 TRENDS
- 3.8 WINNING IMPERATIVES
- 3.8.1 LAUNCH OF APPLICATION DEDICATED SCANNERS
- 3.9 BURNING ISSUES
- 3.9.1 U.S. HEALTHCARE REFORM
- 3.9.2 LACK OF RAW MATERIALS FOR SPECT
- 3.9.3 PET/MRI
- 3.10 EMERGING MARKETS FOR PET
- 3.11 EMERGING THERAPEUTIC USES OF PET
- 3.12 LOW-COST PRODUCTION CENTERS TO LOWER PRICE -TAG
- 3.12.1 GE HEALTHCARE FOCUSING ON INDIA
- 3.12.2 POSITRON CORPORATION'S JV WITH CHINESE COMPANY
- 3.12.3 SIEMENS HEALTHCARE TAPPING MARKET IN EMERGING COUNTRIES
- 3.13 MARKET SHARE ANALYSIS
- 3.13.1 BY KEY PLAYERS
- 3.13.2 BY TECHNOLOGY
- 3.13.3 BY APPLICATIONS
4 PET & SPECT MARKET, BY TECHNOLOGY
- 4.1 PET
- 4.1.1 DRIVERS & RESTRAINTS
- 4.1.1.1 Adequate FDG supply to augment PET scanner market
- 4.1.1.2 Enhanced reimbursement scenario for PET in U.S. to improve
prospects of sales
- 4.1.1.3 Availability of various radioisotopes for organ specific scans
will drive future growth
- 4.1.1.4 Lack of infrastructure - a major lacuna
- 4.2 STANDALONE PET
- 4.2.1 DRIVERS & RESTRAINTS
- 4.2.1.1 Increase in cardiovascular disease incidences to increase the
use of PET scanners
- 4.2.1.2 Dominance of hybrid PET/CT to hamper standalone PET sales
- 4.3 HYBRID PET TECHNOLOGY
- 4.3.1 PET/CT
- 4.3.1.1 Drivers and opportunities
- 4.3.1.1.1 Continuous improvement in PET/CT product lines support
growth in revenue
- 4.3.1.1.2 Role of PET/CT in treatment planning to leverage growth
- 4.3.1.1.3 Development of mobile scanners will drive sales in the
nuclear imaging market
- 4.3.2 PET/MRI
- 4.3.2.1 Superior imaging compared to CT in neurological studies
- 4.4 SPECT
- 4.4.1 DRIVERS & RESTRAINTS
- 4.4.1.1 Low-cost radionuclides to favor the growth of SPECT
- 4.4.1.2 Affordability to drive the sales of SPECT
- 4.4.1.3 Lack of availability of Technetium-99m to affect the SPECT
market
- 4.5 STANDALONE SPECT
- 4.5.1 DRIVERS & RESTRAINTS
- 4.5.1.1 Detection to evaluation of treatment of neurological diseases
drives standalone SPECT market
- 4.5.1.2 Improved treatment for cardiovascular diseases will lead to
increased SPECT sales
- 4.5.1.3 Low spatial resolution & absence of anatomical data - a
negative factor
- 4.6 SPECT/CT
- 4.6.1 DRIVERS
- 4.6.1.1 Advanced technology like Siemens' IQ.SPECT to improve image
quality and thus sales
- 4.6.1.2 Niche application like neuroendocrine tumor imaging to be one
of the major factors to drive SPECT/CT sales
5 PET & SPECT MARKET, BY APPLICATIONS
- 5.1 INTRODUCTION
- 5.2 ONCOLOGY
- 5.3 CARDIOLOGY
- 5.4 NEUROLOGY
6 GEOGRAPHICAL ANALYSIS
- 6.1 INTRODUCTION
- 6.2 U.S. PET-SPECT MARKET
- 6.3 EUROPE PET-SPECT MARKET
- 6.4 APAC PET-SPECT MARKET
- 6.5 JAPAN PET-SPECT MARKET
- 6.6 ROW PET-SPECT MARKET
7 COMPETITIVE LANDSCAPE
- 7.1 COMPETITIVE STRUCTURE
8 COMPANY PROFILES
- 8.1 AGFA-GEVAERT N.V.
- 8.1.1 OVERVIEW
- 8.1.2 PRODUCTS & SERVICES
- 8.1.3 FINANCIALS
- 8.1.4 STRATEGY
- 8.1.5 DEVELOPMENTS
- 8.2 CARDIARC LTD
- 8.2.1 OVERVIEW
- 8.2.2 PRODUCTS & SERVICES
- 8.2.3 FINANCIALS
- 8.2.4 STRATEGY
- 8.2.5 DEVELOPMENTS
- 8.3 COVIDIEN PLC
- 8.3.1 OVERVIEW
- 8.3.2 PRODUCTS & SERVICES
- 8.3.3 FINANCIALS
- 8.3.4 STRATEGY
- 8.3.5 DEVELOPMENTS
- 8.4 DIGIRAD CORPORATION
- 8.4.1 OVERVIEW
- 8.4.2 PRODUCTS & SERVICES
- 8.4.3 FINANCIALS
- 8.4.4 STRATEGY
- 8.4.5 DEVELOPMENTS
- 8.5 GAMMA MEDICA INC
- 8.5.1 OVERVIEW
- 8.5.2 PRODUCTS & SERVICES
- 8.5.3 FINANCIALS
- 8.5.4 STRATEGY
- 8.5.5 DEVELOPMENTS
- 8.6 GE HEALTHCARE
- 8.6.1 OVERVIEW
- 8.6.2 PRODUCTS & SERVICES
- 8.6.3 FINANCIALS
- 8.6.4 STRATEGY
- 8.6.5 DEVELOPMENTS
- 8.7 HOLOGIC INC.
- 8.7.1 OVERVIEW
- 8.7.2 PRODUCTS & SERVICES
- 8.7.3 FINANCIALS
- 8.7.4 STRATEGY
- 8.7.5 DEVELOPMENTS
- 8.8 MEDX INC
- 8.8.1 OVERVIEW
- 8.8.2 PRODUCTS & SERVICES
- 8.8.3 FINANCIALS
- 8.8.4 STRATEGY
- 8.8.5 DEVELOPMENTS
- 8.9 NAVISCAN INC
- 8.9.1 OVERVIEW
- 8.9.2 PRODUCTS & SERVICES
- 8.9.3 FINANCIALS
- 8.9.4 STRATEGY
- 8.9.5 DEVELOPMENTS
- 8.10 POSITRON CORPORATION
- 8.10.1 OVERVIEW
- 8.10.2 PRODUCTS & SERVICES
- 8.10.3 FINANCIALS
- 8.10.4 STRATEGY
- 8.10.5 DEVELOPMENTS
- 8.11 ROYAL PHILIPS ELECTRONICS
- 8.11.1 OVERVIEW
- 8.11.2 PRODUCTS & SERVICES
- 8.11.3 FINANCIALS
- 8.11.4 STRATEGY
- 8.11.5 DEVELOPMENTS
- 8.12 SEGAMI CORPORATION
- 8.12.1 OVERVIEW
- 8.12.2 PRODUCTS & SERVICES
- 8.12.3 FINANCIALS
- 8.12.4 STRATEGY
- 8.12.5 DEVELOPMENTS
- 8.13 SIEMENS HEALTHCARE
- 8.13.1 OVERVIEW
- 8.13.2 PRODUCTS & SERVICES
- 8.13.3 FINANCIALS
- 8.13.4 STRATEGY
- 8.13.5 DEVELOPMENTS
- 8.14 SPECTRUM DYNAMICS LTD
- 8.14.1 OVERVIEW
- 8.14.2 PRODUCTS & SERVICES
- 8.14.3 FINANCIALS
- 8.14.4 STRATEGY
- 8.14.5 DEVELOPMENTS
LIST OF TABLES
- TABLE 1 GLOBAL PET-SPECT MARKET REVENUE, BY TECHNOLOGY, 2009 - 2016
($MILLION)
- TABLE 2 GLOBAL PET-SPECT INSTALLATIONS, BY TECHNOLOGY, 2009 - 2016 (NO. OF
UNITS)
- TABLE 3 WINNING IMPERATIVES FOR PET-SPECT MARKET
- TABLE 4 INVESTMENT IN PET, BY COMPANY
- TABLE 5 GLOBAL PET MARKET REVENUE, BY TECHNOLOGY, 2009 - 2016 ($MILLION)
- TABLE 6 PET MARKET REVENUE, BY GEOGRAPHY, 2009 - 2016 ($MILLION)
- TABLE 7 GLOBAL PET INSTALLATIONS, BY TECHNOLOGY, 2009 - 2016 (NO. OF UNITS)
- TABLE 8 PET INSTALLATIONS, BY GEOGRAPHY, 2009 - 2016 (NO. OF UNITS)
- TABLE 9 STANDALONE PET MARKET, BY GEOGRAPHY, 2009 - 2016 ($MILLION)
- TABLE 10 STANDALONE PET INSTALLATIONS, BY GEOGRAPHY, 2009 - 2016 (NO. OF
UNITS)
- TABLE 11 PET/CT MARKET REVENUE, BY GEOGRAPHY, 2009 - 2016 ($MILLION)
- TABLE 12 PET/CT INSTALLATIONS, BY GEOGRAPHY, 2009 - 2016 (NO. OF UNITS)
- TABLE 13 GLOBAL SPECT MARKET REVENUE, BY TECHNOLOGY, 2009 - 2016 ($MILLION)
- TABLE 14 SPECT MARKET REVENUE, BY GEOGRAPHY, 2009 - 2016 ($MILLION)
- TABLE 15 GLOBAL SPECT INSTALLATIONS, BY TECHNOLOGY, 2009 - 2016 (NO. OF
UNITS)
- TABLE 16 SPECT INSTALLATIONS, BY GEOGRAPHY, 2009 - 2016 (NO. OF UNITS)
- TABLE 17 STANDALONE SPECT MARKET REVENUE, BY GEOGRAPHY, 2009 - 2016
($MILLION)
- TABLE 18 STANDALONE SPECT INSTALLATIONS, BY GEOGRAPHY, 2009 - 2016 (NO. OF
UNITS)
- TABLE 19 SPECT/CT MARKET REVENUE, BY GEOGRAPHY, 2009 - 2016 ($MILLION)
- TABLE 20 SPECT/CT INSTALLATIONS, BY GEOGRAPHY, 2009 - 2016 (NO. OF UNITS)
- TABLE 21 GLOBAL PET MARKET REVENUE, BY APPLICATIONS, 2009 - 2016 ($MILLION)
- TABLE 22 GLOBAL SPECT MARKET REVENUE, BY APPLICATIONS, 2009 - 2016
($MILLION)
- TABLE 23 GLOBAL ONCOLOGY MARKET REVENUE, BY TECHNOLOGY, 2009 - 2016
($MILLION)
- TABLE 24 GLOBAL CARDIOLOGY MARKET REVENUE, BY TECHNOLOGY, 2009 - 2016
($MILLION)
- TABLE 25 GLOBAL NEUROLOGY MARKET REVENUE, BY TECHNOLOGY, 2009 - 2016
($MILLION)
- TABLE 26 PET-SPECT MARKET REVENUE, BY GEOGRAPHY, 2009 - 2016 ($MILLION)
- TABLE 27 PET-SPECT INSTALLATIONS, BY GEOGRAPHY, 2009 - 2016 (NO. OF UNITS)
- TABLE 28 U.S: PET-SPECT MARKET REVENUE, BY TECHNOLOGY, 2009 - 2016
($MILLION)
- TABLE 29 U.S: PET-SPECT INSTALLATIONS, BY TECHNOLOGY, 2009 - 2016 (NO. OF
UNITS)
- TABLE 30 EUROPE: PET-SPECT MARKET REVENUE, BY TECHNOLOGY, 2009 - 2016
($MILLION)
- TABLE 31 EUROPE: PET-SPECT INSTALLATIONS, BY TECHNOLOGY, 2009 - 2016 (NO.
OF UNITS)
- TABLE 32 APAC: PET-SPECT MARKET REVENUE, BY TECHNOLOGY, 2009 - 2016
($MILLION)
- TABLE 33 APAC: PET-SPECT INSTALLATIONS, BY TECHNOLOGY, 2009 - 2016 (NO. OF
UNITS)
- TABLE 34 JAPAN: PET-SPECT MARKET REVENUE, BY TECHNOLOGY, 2009 - 2016
($MILLION)
- TABLE 35 JAPAN: PET-SPECT INSTALLATIONS, BY TECHNOLOGY, 2009 - 2016 (NO.
OF UNITS)
- TABLE 36 ROW: PET-SPECT MARKET REVENUE, BY TECHNOLOGY, 2009 - 2016
($MILLION)
- TABLE 37 ROW: PET-SPECT INSTALLATIONS, BY TECHNOLOGY, 2009 - 2016 (NO. OF
UNITS)
- TABLE 38 MERGERS & ACQUISITIONS, 2008 - 2011
- TABLE 39 NEW PRODUCTS DEVELOPMENT, 2008 - 2011
- TABLE 40 AGREEMENTS & COLLABORATIONS, 2008 - 2011
- TABLE 41 OTHER DEVELOPMENTS, 2008 - 2011
- TABLE 42 AGFA-GEVAERT N.V.: MARKET REVENUE AND R&D EXPENSES, 2008 - 2010
($MILLION)
- TABLE 43 AGFA-GEVAERT N.V.: MARKET REVENUE, BY SEGMENTS, 2008 - 2010
($MILLION)
- TABLE 44 AGFA-GEVAERT N.V.: MARKET REVENUE, BY GEOGRAPHY, 2008 - 2010
($MILLION)
- TABLE 45 COVIDIEN PLC.: MARKET REVENUE AND R&D EXPENSES, 2008 - 2010
($MILLION)
- TABLE 46 COVIDIEN PLC.: MARKET REVENUE, BY SEGMENTS, 2008 - 2010 ($MILLION)
- TABLE 47 COVIDIEN PLC.: MARKET REVENUE, BY GEOGRAPHY, 2008 - 2010
($MILLION)
- TABLE 48 DIGIRAD CORPORATION: MARKET REVENUE AND R&D EXPENSES, 2008 - 2010
($MILLION)
- TABLE 49 DIGIRAD CORPORATION: MARKET REVENUE, BY SEGMENTS, 2008 - 2010
($MILLION)
- TABLE 50 GE HEALTHCARE: MARKET REVENUE AND R&D EXPENSES, 2008 - 2010
($MILLION)
- TABLE 51 GE HEALTHCARE: MARKET REVENUE, BY SEGMENTS, 2008 - 2010 ($MILLION)
- TABLE 52 GE HEALTHCARE: TECHNOLOGY INFRASTRUCTURE MARKET REVENUE, BY
SEGMENTS, 2008 - 2010 ($BILLION)
- TABLE 53 GE HEALTHCARE: MARKET REVENUE, BY GEOGRAPHY, 2008 - 2010
($BILLION)
- TABLE 54 HOLOGIC INC: MARKET REVENUE AND R&D EXPENSES, 2008 - 2010
($MILLION)
- TABLE 55 HOLOGIC INC: MARKET REVENUE, BY SEGMENTS, 2008 - 2010 ($MILLION)
- TABLE 56 POSITRON CORPORATION: MARKET REVENUE AND R&D EXPENSES, 2008 -
2010 ($MILLION)
- TABLE 57 PHILIPS ELECTRONICS: MARKET REVENUE AND R&D EXPENSES, 2008 - 2010
($MILLION)
- TABLE 58 PHILIPS ELECTRONICS: MARKET REVENUE, BY SEGMENTS, 2008 - 2010
($MILLION)
- TABLE 59 PHILIPS ELECTRONICS: MARKET REVENUE, BY GEOGRAPHY, 2008 - 2010
($MILLION)
- TABLE 60 SIEMENS: MARKET REVENUE AND R&D EXPENSES, 2008 - 2010 ($MILLION)
- TABLE 61 SIEMENS: MARKET REVENUE, BY SEGMENTS, 2008 - 2010 ($MILLION)
- TABLE 62 SIEMENS: MARKET REVENUE, BY GEOGRAPHY, 2008 - 2010 ($MILLION)
LIST OF FIGURES
- FIGURE 1 EVOLUTION OF PET
- FIGURE 2 EVOLUTION OF SPECT
- FIGURE 3 PET VS SPECT
- FIGURE 4 GLOBAL MARKET SHARE OF PET & SPECT END-USERS (2003 VS 2010)
- FIGURE 5 MARKET DYNAMICS OF PET-SPECT MARKET
- FIGURE 6 EVALUATION OF EMERGING COUNTRIES IN MARKET COMPETITIVENESS
- FIGURE 7 EMERGING THERAPEUTIC USES OF PET
- FIGURE 8 GLOBAL PET-SPECT MARKET REVENUE, BY KEY PLAYERS, 2011
- FIGURE 9 GLOBAL PET-SPECT MARKET REVENUE, BY TECHNOLOGY, 2011
- FIGURE 10 GLOBAL PET-SPECT INSTALLATIONS, BY TECHNOLOGY, 2011
- FIGURE 11 GLOBAL PET-SPECT MARKET REVENUE, BY APPLICATIONS, 2011
- FIGURE 12 POTENTIAL CLINICAL APPLICATIONS OF PET/MRI
- FIGURE 13 STRATEGIC DEVELOPMENTS, 2008 - 2011
|
